Related Experiment Video
Updated: Aug 18, 2026
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage
Guorong Li1, Gang Cui, Nian-Ssheng Tzeng
1Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA. guorongl@med.unc.edu
Abstract:
Inflammation in the brain has increasingly been recognized to play an important role in the pathogenesis of several neurodegenerative disorders, including Parkinson's disease (PD). Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. We previously showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used antitussive remedies, reduced the inflammation-mediated degeneration of dopaminergic neurons through the inhibition of microglial activation. In this study, we report that femto- and micromolar concentrations of DM (both pre- and post-treatment) showed equal efficacy in protecting lipopolysaccharide (LPS) -induced dopaminergic neuron death in midbrain neuron-glia cultures. Both concentrations of DM decreased LPS-induced release of nitric oxide, tumor necrosis factor-alpha, prostaglandin E2 and superoxide from microglia in comparable degrees. The important role of superoxide was demonstrated by DM's failure to show a neuroprotective effect in neuron-glia cultures from NADPH oxidase-deficient mice. These results suggest that the neuroprotective effect elicited by femtomolar concentrations of DM is mediated through the inhibition of LPS-induced proinflammatory factors, especially superoxide. These findings suggest a novel therapeutic concept of using "ultra-low" drug concentrations for the intervention of inflammation-related neurodegenerative diseases.
Insights
Dextromethorphan (DM) protects brain cells from inflammation-related damage at ultra-low concentrations. This suggests a new therapeutic approach for neurodegenerative diseases like Parkinson's disease (PD).
Area of Science:
- Neuroscience
- Neuroinflammation
- Pharmacology
Background:
- Brain inflammation is a key factor in neurodegenerative diseases such as Parkinson's disease (PD).
- Current therapeutic strategies to halt neurodegeneration are limited.
- Dextromethorphan (DM) at micromolar concentrations previously showed neuroprotective effects by inhibiting microglial activation.
Purpose of the Study:
- To investigate the neuroprotective efficacy of ultra-low (femtomolar) concentrations of Dextromethorphan (DM) against inflammation-induced dopaminergic neuron death.
- To elucidate the mechanisms underlying DM's neuroprotective effects, particularly the role of superoxide.
Main Methods:
- Utilized midbrain neuron-glia cultures exposed to lipopolysaccharide (LPS) to induce dopaminergic neuron death.
- Administered Dextromethorphan (DM) at femtomolar and micromolar concentrations (pre- and post-treatment).
- Assessed the release of inflammatory mediators (nitric oxide, TNF-alpha, PGE2, superoxide) from microglia.
- Compared DM's efficacy in wild-type and NADPH oxidase-deficient neuron-glia cultures.
Main Results:
- Both femtomolar and micromolar concentrations of DM demonstrated equal efficacy in protecting dopaminergic neurons from LPS-induced death.
- DM significantly reduced LPS-induced release of nitric oxide, tumor necrosis factor-alpha, prostaglandin E2, and superoxide from microglia.
- DM's neuroprotective effect was abolished in cultures from NADPH oxidase-deficient mice, highlighting the critical role of superoxide.
Conclusions:
- Femtomolar concentrations of Dextromethorphan (DM) exert significant neuroprotection against inflammation-induced dopaminergic neuron death.
- The protective mechanism involves the inhibition of LPS-induced inflammatory factors, with a key role for superoxide reduction.
- Ultra-low drug concentrations represent a novel therapeutic concept for managing inflammation-related neurodegenerative diseases.
